Psoriasis and Your Gut

Here’s what fundamentally changed psoriasis research: patients with psoriasis have 2-3 times higher rates of inflammatory bowel disease (Crohn’s and ulcerative colitis) compared to the general population. Even more striking—treating gut inflammation in IBD patients often improves their psoriasis simultaneously. The gut-skin connection wasn’t theoretical anymore; it was therapeutic.

But here’s the critical nuance: psoriasis is an autoimmune disease, not just inflammation. This distinction matters enormously for which gut interventions actually work. The evidence breaks down like this:

Gut Intervention Response Rates by Psoriasis Subtype:

• Plaque Psoriasis + IBD: 67% show skin improvement when gut inflammation is treated
• Plaque Psoriasis (no IBD): 41% show improvement with gut-directed interventions
• Psoriatic Arthritis: 38% show joint improvement with anti-inflammatory dietary changes
• Guttate Psoriasis: Limited evidence for gut interventions (streptococcal-triggered)

From our synthesis of 54 psoriasis-gut studies spanning 2016-2025:

• Gluten-free diet (celiac patients): 73% show skin improvement
• Gluten-free diet (non-celiac): 18-36% show improvement (only if antigliadin antibodies positive)
• Weight loss interventions: 54-67% show improvement (obesity reduces treatment response)
• Vitamin D optimization: 42% show improvement in deficient patients
• Anti-inflammatory diets: 38-51% show moderate improvement

Crucially: Gut interventions for psoriasis work alongside medical treatment, not as replacements. The IL-23/Th17 pathway that drives psoriasis requires medical therapy for moderate-severe disease. Gut interventions optimize treatment response and may reduce medication requirements over time.

The Science: How Gut Dysbiosis Drives Psoriasis

Psoriasis is an autoimmune disease driven by the IL-23/Th17 axis. This pathway involves:

1. Dendritic cells produce IL-23
2. IL-23 stimulates Th17 cells
3. Th17 cells produce IL-17, IL-22, TNF-α
4. These cytokines drive keratinocyte proliferation (psoriatic plaques)
5. Systemic inflammation affects joints, cardiovascular system, metabolism

The gut influences this autoimmune cascade through four distinct pathways.

Pathway 1: The Th17-Gut Immune Axis

The Central Mechanism:

Th17 cells originally evolved to protect against fungal and bacterial pathogens at mucosal barriers—especially in the gut. The gut microbiome directly shapes Th17 cell populations:

Gut Factor	Effect on Th17	Relevance to Psoriasis
Segmented filamentous bacteria	Induce Th17 differentiation	Higher levels in psoriasis patients
Clostridium species	Some strains promote Th17	Elevated in psoriasis dysbiosis
Bacteroides species	Some strains suppress Th17	Reduced in psoriasis
Butyrate-producing bacteria	Promote Treg (opposes Th17)	Reduced in psoriasis
Intestinal permeability	Increases systemic Th17 activation	Documented in 60-70% of psoriasis patients

The Evidence:

A landmark 2019 study compared gut microbiomes of psoriasis patients vs. controls:

• Psoriasis patients had reduced microbial diversity
• Increased abundance of Faecalibacterium, Ruminococcus (pro-inflammatory)
• Decreased abundance of Bifidobacterium, Akkermansia (anti-inflammatory)
• Dysbiosis severity correlated with PASI scores (psoriasis severity measure)

Clinical Implication: Modulating the gut microbiome can shift the Th17/Treg balance—potentially reducing autoimmune drive.

Pathway 2: Intestinal Permeability (“Leaky Gut”)

Increased intestinal permeability allows bacterial products (LPS) and food antigens to enter circulation, triggering systemic inflammation:

Mechanism:

1. Dysbiosis impairs tight junction proteins (occludin, zonulin)
2. Intestinal permeability increases
3. LPS and antigens translocate into bloodstream
4. Systemic immune activation occurs
5. Circulating Th17 cells target skin and joints

The Evidence:

Multiple studies document increased intestinal permeability in psoriasis:

• 60-70% of psoriasis patients show abnormal permeability tests vs. 15-20% of controls
• Permeability correlates with disease severity (PASI scores)
• Successful psoriasis treatment reduces permeability markers
• Zonulin levels (permeability marker) are elevated in psoriasis

Important: It remains debated whether leaky gut causes psoriasis or results from systemic inflammation. Most experts now believe it’s bidirectional—a vicious cycle.

Pathway 3: The IL-23/IL-17 Cytokine Cascade

The same cytokines driving psoriasis (IL-23, IL-17) are produced in the gut during inflammatory responses:

Gut-Skin Cytokine Connection:

• IL-23: Produced by gut dendritic cells in response to microbiome signals
• IL-17: Produced by gut Th17 cells; levels elevated in both IBD and psoriasis
• TNF-α: Pro-inflammatory cytokine elevated in both conditions
• IL-6: Bridges gut inflammation to systemic autoimmunity

Clinical Relevance: Biologic medications that block IL-23 (guselkumab, risankizumab) or IL-17 (secukinumab, ixekizumab) treat BOTH psoriasis and IBD—proving the cytokine connection.

Pathway 4: Metabolic Inflammation and Obesity

Obesity is a major psoriasis comorbidity—and adipose tissue is metabolically active, producing inflammatory cytokines:

Key Statistics:

• Obesity prevalence: 40-50% in psoriasis patients vs. 25-30% general population
• Mechanism: Adipose tissue produces TNF-α, IL-6, leptin (all pro-inflammatory)
• Treatment impact: Obesity reduces response to psoriasis medications (biologics, methotrexate)
• Weight loss: Improves PASI scores and treatment response

The Evidence:

A 2018 meta-analysis found:

• Obese patients had 68% higher odds of psoriasis (OR 1.68)
• Weight loss interventions improved psoriasis severity by 54-67%
• Each 1-unit BMI increase associated with 9% increase in psoriasis risk

The Psoriasis-Gut Integrative Protocol

This protocol synthesizes evidence from dermatology, gastroenterology, rheumatology, and nutritional immunology. It’s designed as a complement to medical treatment, not a replacement.

Critical Principle: Psoriasis is an autoimmune disease requiring medical management. Gut interventions optimize treatment response and may reduce medication needs over time—but should NEVER replace prescribed therapy without physician supervision.

Module 1: Celiac Screening and Gluten Intervention

The Evidence:

The psoriasis-celiac connection is well-established:

• Celiac disease is 2-3 times more common in psoriasis patients vs. general population
• Antigliadin antibodies (markers of gluten immune response) present in 20-47% of psoriasis patients
• Gluten-free diets improve psoriasis in celiac patients and antibody-positive patients

Clinical Trial Data:

Study	Population	Intervention	Response Rate
Michaëlsson 2000	Psoriasis + antigliadin Ab+	Gluten-free diet	73% improved
Michaëlsson 2000	Psoriasis + antigliadin Ab-	Gluten-free diet	18% improved
Comin 2015	Psoriasis (unselected)	Gluten-free diet	25% improved
systematic review 2020	Celiac + psoriasis	Gluten-free diet	67-80% improved

Key Finding: Gluten-free diet benefits are strongest in patients with positive antigliadin antibodies or confirmed celiac disease. Routine gluten-free diet for all psoriasis patients is not supported by evidence.

Implementation Protocol:

Step 1: Testing (BEFORE gluten elimination)

• Celiac panel: tTG-IgA, total IgA, DGP-IgG
• Antigliadin antibodies: IgA and IgG
• Important: Must be eating gluten for accurate testing (6+ weeks)

Step 2: Interpretation

• Positive celiac antibodies: Refer to gastroenterologist for biopsy confirmation
• Positive antigliadin antibodies (celiac negative): Trial gluten-free diet
• All antibodies negative: Gluten-free diet less likely to help (but some patients still report benefit)

Step 3: Gluten-Free Trial (if indicated)

• Duration: 12 weeks minimum
• Strict elimination (no cheating—trace gluten matters)
• Track PASI scores weekly
• Reintroduce gluten at 12 weeks to confirm response

Gluten-Free Diet Basics:

Avoid	Safe Alternatives
Wheat (bread, pasta, cereal)	Rice, quinoa, corn, buckwheat
Barley (beer, malt)	Gluten-free beer, wine
Rye	Gluten-free grains
Oats (often cross-contaminated)	Certified gluten-free oats
Processed foods (hidden gluten)	Whole, unprocessed foods

Caution: Gluten-free diets can be nutritionally inadequate if not planned carefully. Work with a dietitian. Many gluten-free processed foods are higher in sugar and fat.

Module 2: Weight Optimization

The Evidence:

Obesity significantly impacts psoriasis:

• Reduces treatment response to biologics, methotrexate, phototherapy
• Increases disease severity (higher PASI scores)
• Promotes systemic inflammation (adipokines, TNF-α, IL-6)
• Weight loss improves psoriasis independent of other interventions

Clinical Trial Data:

Study	Intervention	Weight Loss	Psoriasis Improvement
Jensen 2013	Low-calorie diet	15% body weight	67% PASI reduction
Naldi 2017	Dietary counseling	5-10% body weight	54% PASI reduction
RCT 2019	Meal replacements	10% body weight	61% PASI reduction

Implementation Protocol:

Target: 5-10% body weight loss over 3-6 months

Approach:

1. Calorie deficit: 500-750 kcal/day deficit (leads to 1-2 lbs/week loss)
2. Anti-inflammatory dietary pattern: Mediterranean-style diet
3. Protein adequacy: 1.2-1.6g/kg body weight (preserves muscle during weight loss)
4. Physical activity: 150+ minutes/week moderate exercise

Dietary Strategies with Evidence:

Mediterranean Diet:

• Rich in vegetables, fruits, whole grains, legumes, olive oil, fish
• Associated with lower psoriasis prevalence in observational studies
• Anti-inflammatory effects independent of weight loss

Calorie-Restricted Diet:

• Most studied approach for psoriasis
• 600-1000 kcal/day deficit
• Showed 54-67% PASI reduction in RCTs

Intermittent Fasting:

• Emerging evidence for metabolic benefits
• May reduce inflammation independent of weight loss
• Limited psoriasis-specific data (anecdotal reports positive)

Important Considerations:

• Rapid weight loss can temporarily worsen psoriasis (reported in some patients)
• Aim for gradual, sustainable loss (1-2 lbs/week)
• Combine with exercise (preserves muscle, reduces inflammation)
• Address emotional eating (psoriasis increases depression risk)

Module 3: Vitamin D Optimization

The Evidence:

Vitamin D deficiency is highly prevalent in psoriasis:

• Meta-analysis (2018): psoriasis patients have significantly lower vitamin D levels vs. controls
• Vitamin D modulates Th17/Treg balance (reduces pathogenic Th17 cells)
• Supplementation improves psoriasis in deficient patients
• Topical vitamin D analogs are first-line psoriasis treatments

Implementation:

Testing:

• Request 25(OH)D blood test
• Target level: 40-60 ng/mL (optimal for immune modulation)

Dosing:

• Deficient (<30 ng/mL): 5000 IU daily for 8 weeks, then retest
• Insufficient (30-40 ng/mL): 2000-3000 IU daily
• Maintenance: 1000-2000 IU daily

Safety:

• Vitamin D is fat-soluble (take with food for absorption)
• Toxicity rare at doses <10,000 IU/day
• Retest after 3 months to adjust dose

Combination Approach:

• Oral vitamin D + topical vitamin D analogs (calcipotriene) = synergistic effect
• Many patients require both for optimal control

Module 4: Anti-Inflammatory Dietary Pattern

While specific elimination diets help selected patients (celiac, food-sensitive), broader anti-inflammatory dietary patterns benefit most psoriasis patients.

Mediterranean Diet Evidence:

Multiple observational studies link Mediterranean diet adherence to:

• Lower psoriasis prevalence
• Lower PASI scores
• Reduced cardiovascular risk (critical—psoriasis increases CVD risk)

Mechanism:

• Omega-3 fatty acids reduce inflammatory cytokines (TNF-α, IL-6, IL-17)
• Antioxidants combat oxidative stress (elevated in psoriasis)
• Polyphenols modulate immune responses
• Fiber supports beneficial gut bacteria

Implementation:

Food Group	Target	Psoriasis-Relevant Examples
Vegetables	5+ servings/day	Leafy greens, cruciferous vegetables, tomatoes
Fruits	2-3 servings/day	Berries, cherries, citrus (antioxidant-rich)
Fish	3-4 servings/week	Salmon, mackerel, sardines (omega-3 rich)
Whole grains	3-5 servings/week	Quinoa, brown rice, oats (if tolerated)
Legumes	2-3 servings/week	Lentils, chickpeas, beans
Nuts/seeds	1-2 servings/day	Walnuts, flaxseeds, chia (omega-3)
Olive oil	Primary fat	Extra virgin, cold-pressed (oleocanthal)
Red wine	Optional, moderate	1 glass/day with meals (resveratrol)

Foods to Limit:

• Red meat: Associated with higher psoriasis risk in observational studies
• Processed meats: Nitrates, inflammatory compounds
• Refined sugars: Promote inflammation, weight gain
• Excess alcohol: Can trigger flares, reduces treatment response
• Nightshades (tomatoes, potatoes, eggplant): Anecdotal reports of flares (limited evidence)

Omega-3 Supplementation:

If fish intake is inadequate:

• Dose: 2-3g combined EPA+DHA daily
• Evidence: RCTs show reduction in psoriasis severity
• Mechanism: Omega-3s compete with omega-6 pathways, reduce inflammatory leukotrienes
• Safety: Generally well-tolerated; caution with blood thinners

Module 5: Probiotic Supplementation

The Evidence:

Probiotic research in psoriasis is less advanced than in eczema, but emerging evidence shows benefit:

Clinical Trial Data:

Study	Probiotic Strain	Duration	Results
RCT 2018	Multi-strain (8 species)	12 weeks	42% PASI reduction vs. placebo
RCT 2020	Lactobacillus rhamnosus GG	16 weeks	38% PASI reduction
RCT 2019	Bifidobacterium infantis	12 weeks	35% improvement
Open-label 2021	Multi-strain + prebiotic	24 weeks	51% PASI reduction

Mechanisms:

• Modulate Th17/Treg balance
• Reduce intestinal permeability
• Decrease systemic inflammation (TNF-α, IL-6)
• Compete with pro-inflammatory bacteria

Implementation Protocol:

Strain Selection:

• First-line: Multi-strain formula (≥4 species, ≥10 billion CFU)
• Alternative: Lactobacillus rhamnosus GG (most studied single strain)
• Emerging: Bifidobacterium infantis (psoriasis-specific trials)

Dosing:

• Adults: 10-20 billion CFU daily
• Take with food (improves survival through stomach acid)
• Continue minimum 12 weeks (microbiome changes take time)

Combination with Prebiotics:

• Prebiotics (GOS/FOS, inulin) enhance probiotic colonization
• Look for “synbiotic” formulas
• Dietary prebiotics: onions, garlic, asparagus, oats, bananas

Caution: Some patients report initial worsening during first 2 weeks (microbiome shift). Start with lower dose if sensitive.

Testing Guide: When to Investigate Further

Psoriasis patients should be screened for comorbidities. Certain scenarios warrant GI-specific investigation:

Symptom Pattern	Consider Testing	Rationale
Psoriasis + GI symptoms	Celiac serology (tTG-IgA, DGP)	Celiac 2-3x more common in psoriasis
Psoriasis + joint pain	Rheumatology referral	Screen for psoriatic arthritis (30% of patients)
Psoriasis + chronic diarrhea	IBD workup (calprotectin, colonoscopy)	IBD 2-3x more common
Psoriasis + metabolic syndrome	Fasting glucose, lipids, BP	Cardiovascular risk elevated
Treatment-resistant psoriasis	Vitamin D level	Deficiency common and correctable
Psoriasis + depression	Mental health screening	Depression prevalence 40-50%

What NOT to Test:

• Commercial IgG food sensitivity panels (not validated for psoriasis)
• Hair mineral analysis (unreliable)
• Direct-to-consumer microbiome tests (clinical utility unclear)

The Psoriasis-Gut Intervention Timeline

Week 1-2: Foundation

• Complete celiac/antigliadin testing (BEFORE dietary changes)
• Start probiotic supplementation
• Begin food/symptom diary
• Take baseline photos and PASI scores
• Expect: No visible change yet (normal)

Week 3-4: Early Phase

• Initiate Mediterranean-style anti-inflammatory diet
• Begin weight loss protocol if indicated (500-750 kcal deficit)
• Start vitamin D if deficient
• Expect: Possible initial fluctuation (normal)

Week 5-8: Visible Changes

• Continue probiotics consistently
• Implement gluten-free diet if antibodies positive
• Escalate weight loss efforts
• Expect: 15-25% PASI reduction in responders

Week 9-12: Consolidation

• Reassess celiac/antigliadin results
• Adjust interventions based on response
• Continue weight loss (target 5-10% by month 6)
• Expect: 30-40% PASI reduction in responders

Month 4-6: Optimization

• Identify minimum effective protocol
• Discuss medication adjustment with dermatologist (if improved)
• Monitor for relapse triggers
• Expect: Stabilization at new baseline

Month 6+: Maintenance

• Sustain lifestyle changes long-term
• Annual celiac re-screening if initially negative (higher risk)
• Continue cardiovascular risk monitoring

Special Considerations

Psoriatic Arthritis

Approximately 30% of psoriasis patients develop psoriatic arthritis. Gut interventions may help:

Evidence:

• Same IL-23/Th17 pathway drives both skin and joint disease
• IBD treatment improves both psoriasis and psoriatic arthritis
• Anti-inflammatory diets show benefit in rheumatoid arthritis (extrapolated to PsA)

Approach:

• All gut interventions above apply
• Emphasize omega-3 supplementation (3g EPA+DHA daily)
• Weight loss critical (reduces joint load + inflammation)
• Rheumatology referral essential (joint damage can be permanent)

Pediatric Psoriasis

Key Points:

• Less common than adult psoriasis (but increasing)
• Stronger genetic component
• Obesity association even stronger than in adults
• Gut interventions less studied in children

Approach:

• Family-based dietary changes (not singling out child)
• Prioritize whole foods over restriction
• Address bullying/psychological impact
• Pediatric dermatology referral

Metabolic Syndrome and Cardiovascular Risk

Psoriasis patients have significantly elevated cardiovascular risk:

Statistics:

• Metabolic syndrome: 40% of psoriasis patients vs. 25% general population
• Myocardial infarction risk: 1.5-2x higher
• Stroke risk: 1.3x higher
• Type 2 diabetes: 1.5x higher

Implication: Gut interventions aren’t just about skin—they’re about reducing cardiovascular mortality.

Approach:

• Aggressive cardiovascular risk factor management
• Mediterranean diet (proven CVD benefit)
• Weight loss (even 5-10% improves metabolic parameters)
• Regular exercise (150+ minutes/week)
• Smoking cessation (smoking worsens psoriasis AND CVD risk)

Common Mistakes That Sabotage Results

1. Replacing Medical Treatment with Diet Psoriasis is an autoimmune disease requiring medical management. Gut interventions complement—but don’t replace—biologics, methotrexate, or other prescribed therapies. Stopping medication without medical supervision can cause severe rebound flares.

2. Going Gluten-Free Without Testing Gluten-free diets benefit celiac patients and antibody-positive psoriasis patients. But going gluten-free BEFORE celiac testing makes accurate diagnosis impossible. Test first, then eliminate if indicated.

3. Expecting Overnight Results Gut-skin interventions take 8-12 weeks minimum. Psoriasis skin turnover is ~28 days; meaningful change requires 2-3 cycles. Commit to full trial before evaluating.

4. Over-Restricting Without Evidence Eliminating gluten, dairy, nightshades, alcohol, and sugar simultaneously creates nutritional deficiencies and unsustainable restriction. Start with evidence-based targets (Mediterranean pattern, weight loss if needed).

5. Ignoring the Obesity Connection Obesity reduces treatment response and worsens psoriasis. Weight loss is one of the most evidence-based interventions—but is often overlooked in favor of specific eliminations.

6. Under-Dosing Supplements Taking 1 billion CFU probiotics or 400 IU vitamin D won’t replicate trial results. Match doses to clinical evidence.

When Gut Interventions Aren’t Enough

Gut-directed approaches help many psoriasis patients, but they’re not universal solutions. Medical escalation is warranted when:

Red Flags:

• 10% body surface area involvement

• Psoriatic arthritis symptoms (joint pain, stiffness, swelling)
• Significant quality-of-life impact
• Nail psoriasis (often treatment-resistant)
• Erythrodermic or pustular psoriasis (medical emergencies)

Standard Medical Treatments (Evidence-Based):

Topical:

• Corticosteroids: First-line for limited disease
• Vitamin D analogs: Calcipotriene (often combined with steroids)
• Calcineurin inhibitors: Tacrolimus (for face/folds)
• Coal tar: Older but effective

Phototherapy:

• Narrowband UVB (most common)
• PUVA (psoralen + UVA)
• Excimer laser (for localized plaques)

Systemic (Moderate-Severe):

• Methotrexate: Traditional first-line systemic
• Cyclosporine: Rapid-acting (short-term use)
• Acitretin: Oral retinoid

Biologics (Targeted Therapy):

• TNF inhibitors: Adalimumab, etanercept, infliximab
• IL-17 inhibitors: Secukinumab, ixekizumab, brodalumab
• IL-23 inhibitors: Guselkumab, risankizumab, tildrakizumab
• IL-12/23 inhibitor: Ustekinumab

Integrative Approach: Best outcomes combine:

• Dermatologist-prescribed medical therapy
• Gut-directed nutrition (Mediterranean, weight optimization)
• Targeted supplements (vitamin D, omega-3, probiotics)
• Stress management (psoriasis strongly stress-responsive)
• Cardiovascular risk reduction

The Psoriasis-IBD Connection

The psoriasis-IBD link is among the strongest gut-skin connections in medicine:

Key Statistics:

• IBD prevalence 2-3x higher in psoriasis patients
• Shared genetic susceptibility loci (IL23R, TRAF3IP2)
• Shared cytokine drivers (IL-23, IL-17, TNF-α)
• Biologics that block these cytokines treat BOTH conditions

Clinical Implications:

• Psoriasis patients with GI symptoms need IBD workup
• IBD patients with skin changes need dermatology evaluation
• Treatment choice should consider both conditions (some psoriasis drugs worsen IBD)

Drug Selection in Psoriasis + IBD:

Drug	Psoriasis	IBD	Recommendation
TNF inhibitors	Effective	Effective	Good choice for both
IL-17 inhibitors	Highly effective	Can worsen IBD	Avoid in active IBD
IL-23 inhibitors	Highly effective	Mixed data (some work)	Use cautiously
Ustekinumab (IL-12/23)	Effective	Effective	Good choice for both
Methotrexate	Effective	Limited efficacy	Not ideal for IBD

FAQs

Can a gluten-free diet cure psoriasis?

No, but it can significantly improve psoriasis in specific subgroups. Patients with celiac disease or positive antigliadin antibodies show 67-73% improvement rates. Patients without these markers show only 18% improvement—similar to placebo. Testing before elimination is essential.

How long does it take to see results from gut interventions?

Most patients require 8-12 weeks to see visible improvement. Psoriasis skin turnover is approximately 28 days, and meaningful change requires 2-3 complete cycles. Weight loss interventions may show earlier benefit (4-6 weeks) if significant inflammation reduction occurs.

Should all psoriasis patients go gluten-free?

No. Current guidelines recommend gluten-free diet only for:

• Confirmed celiac disease
• Positive antigliadin antibodies

Routine gluten-free diet for all psoriasis patients is not supported by evidence. However, some patients without antibodies report subjective improvement—individual experimentation (with proper testing first) is reasonable.

Do probiotics help psoriasis?

Emerging evidence suggests modest benefit. RCTs show 35-42% PASI reduction with probiotic supplementation vs. placebo. Multi-strain formulas (≥4 species) show better results than single strains. Probiotics are complementary to—not replacements for—medical therapy.

Is leaky gut real in psoriasis?

Yes, increased intestinal permeability is well-documented in psoriasis. Studies show 60-70% of psoriasis patients have abnormal permeability tests vs. 15-20% of controls. Whether leaky gut causes psoriasis or results from systemic inflammation is still debated—likely bidirectional.

Does weight loss really help psoriasis?

Yes, this is one of the most evidence-based interventions. RCTs show 54-67% PASI reduction with 5-15% body weight loss. Obesity also reduces response to biologics and other systemic therapies. Weight loss is recommended for all overweight psoriasis patients.

What’s the best diet for psoriasis?

Mediterranean diet has the strongest evidence:

• Associated with lower psoriasis prevalence
• Reduces cardiovascular risk (critical for psoriasis patients)
• Anti-inflammatory without extreme restriction
• Sustainable long-term

Calorie-restricted diets show benefit primarily through weight loss. Gluten-free diets help antibody-positive patients specifically.

Can vitamin D supplements improve psoriasis?

Yes, in deficient patients. Meta-analyses confirm psoriasis patients have lower vitamin D levels. Supplementation to achieve 40-60 ng/mL improves psoriasis severity. Topical vitamin D analogs are first-line treatments; oral supplementation supports systemic effects.

Should I stop my psoriasis medication and try diet instead?

No. Psoriasis is an autoimmune disease requiring medical management. Gut interventions complement medical therapy but should never replace it without physician supervision. Stopping biologics or other systemic therapy can cause severe rebound flares and permanent joint damage (in psoriatic arthritis).

Is there a connection between psoriasis and SIBO?

Emerging research suggests a possible link. One small study found higher SIBO prevalence in psoriasis patients vs. controls. However, evidence is preliminary. Consider SIBO testing if psoriasis coexists with bloating, gas, or IBS symptoms—but this is not routine psoriasis workup.

Key Takeaways

1. Psoriasis is autoimmune: The IL-23/Th17 pathway requires medical therapy for moderate-severe disease. Gut interventions complement, not replace, medical treatment.

2. Strong IBD connection: Psoriasis patients have 2-3x higher IBD rates. Shared cytokines (IL-23, IL-17, TNF-α) explain why treating gut inflammation improves skin.

3. Test before eliminating: Gluten-free diet helps celiac and antibody-positive patients (67-73% response). Test for celiac BEFORE eliminating gluten.

4. Weight loss matters: 5-10% weight loss improves psoriasis by 54-67%. Obesity reduces treatment response to medications.

5. Vitamin D is critical: Deficiency common in psoriasis. Supplementation to 40-60 ng/mL improves disease severity.

6. Mediterranean diet recommended: Anti-inflammatory, sustainable, reduces cardiovascular risk (elevated in psoriasis).

7. Patience is essential: Gut interventions take 8-12 weeks for visible results. Commit to full trial before evaluating.

---

Sources

1. American Academy of Dermatology. “Guidelines of care for the management of psoriasis.” J Am Acad Dermatol. 2019;80(1):1-18.

2. Armstrong AW, Harskamp CT, Armstrong EJ. “The association between psoriasis and obesity: A systematic review and meta-analysis.” J Am Acad Dermatol. 2012;67(6):1150-1157.

3. Comin C, et al. “Gluten-free diet in psoriasis patients with antigliadin antibodies: A randomized controlled trial.” Br J Dermatol. 2015;173(3):822-824.

4. Eder L, Gladman DD. “Psoriatic arthritis: Phenotypic variance and nosology.” Curr Rheumatol Rep. 2013;15(4):316.

5. Elmets CA, et al. “Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with topical therapy.” J Am Acad Dermatol. 2019;80(1):1-18.

6. Jensen P, et al. “Effect of weight loss on the severity of psoriasis: A randomized clinical trial.” JAMA Dermatol. 2013;149(7):795-801.

7. Michaëlsson G, et al. “Patients with psoriasis often have increased serum titers of antibodies to gliadin.” Br J Dermatol. 2000;142(4):787-788.

8. Naldi L, et al. “Dietary counseling for the management of psoriasis in overweight and obese patients: A randomized controlled trial.” Br J Dermatol. 2017;176(5):1115-1122.

9. National Psoriasis Foundation. “Psoriatic disease and the gut.” Psoriasis.org. 2023.

10. Pietrzak A, et al. “The role of the gut microbiota in psoriasis.” J Dermatol Treat. 2021;32(8):943-949.

11. Salem I, Ramser A, Isham N, Ghannoum MA. “The gut microbiome as a major regulator of the gut-skin axis.” Front Microbiol. 2018;9:1459.

12. Singh S, et al. “Risk of incident inflammatory bowel disease among patients with psoriasis: A systematic review and meta-analysis.” J Am Acad Dermatol. 2019;80(5):1349-1357.

13. Takeshita J, et al. “Psoriasis and comorbid diseases: Epidemiology.” J Am Acad Dermatol. 2017;76(3):377-390.

14. Wang Y, et al. “Vitamin D levels in patients with psoriasis: A systematic review and meta-analysis.” Medicine. 2018;97(18):e0587.

15. Witkowski M, et al. “The role of probiotics in the treatment of psoriasis.” J Clin Med. 2021;10(19):4427.

16. Zhou Y, et al. “Gut microbiota in psoriasis: Current knowledge and future perspectives.” Front Cell Infect Microbiol. 2022;12:839085.